Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03235089 · ClinicalTrials.gov registry record · NA

A 6-Hour Clinical Evaluation of New Daily-Wear Soft Contact Lenses

A NA study of Myopia, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT03235089: Completed NA study of Myopia, sponsored by CooperVision.

NCT03235089 is a NA study of Myopia that has completed, run by CooperVision. The registered enrollment target is 31 participants, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03235089, a NA study of Myopia, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to validate the clinical performance of a new contact lens design when worn over a period of 6 hours compared to nelfilcon A (control).

Primary Outcome

Horizontal Lens Centration assessed in primary gaze was measured in 0.1mm steps. (mm-nasal decentration given +ve value, temporal decentration given -ve value)

Conditions Studied

Interventions

  • DEVICE Test Lens
  • DEVICE Control Lens

Study Locations (1)

Indiana

  • Clinical Optics Research Lab (CORL) Indiana University School of Optometry, Indiana University - Bloomington

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2017-07-25
Est. Completion 2017-08-03
Phase NA
CooperVision

64 total trials

What the finished NCT03235089 record still lists

NCT03235089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 268-participant average among 90 other Myopia trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Test Lens is the first listed.

NCT03235089 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT03235089 about?

NCT03235089 is a clinical study titled "A 6-Hour Clinical Evaluation of New Daily-Wear Soft Contact Lenses". The purpose of this study is to validate the clinical performance of a new contact lens design when worn over a period of 6 hours compared to nelfilcon A (control).

What is the current status of trial NCT03235089?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2017-07-25. Estimated completion is 2017-08-03.

What conditions does trial NCT03235089 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT03235089?

The interventions under investigation include: Test Lens (DEVICE), Control Lens (DEVICE).

Who is sponsoring clinical trial NCT03235089?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03235089 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03235089's enrollment target sits among peer trials

31 85th of 90 higher than 6 of 90 other Myopia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03235089, the US trial registry maintained by the National Library of Medicine. NCT03235089 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.